Awards for UMIP Premier Fund investments
Renephra and Myconostica are part of the UMIP Premier Fund which is managed by technology specialists MTI Partners, who invest in hi-tech, high growth companies.
Myconostica was awarded the ‘Innovation in Diagnostics Project of the Year’, at this year’s Northwest Biomedical Awards dinner, whilst Renephra received the ‘Emerging Technology Project of the Year’ at the same ceremony, but also scooped a ‘Northwest NHS Innovations Award’ at a separate event.
University of Manchester School of Medicine spin out, Myconostica, is a medical diagnostic company which develops and commercialises rapid and highly specific tests for life-threatening fungal infections. The award was received for Myconostica’s MycArray Yeast ID product; an inventive system for identifying Candida species.
Renephra, also a spin out project from The University of Manchester, were recognised for the development of their groundbreaking dialysis technology that could dramatically improve the quality of life of patients with kidney disease and improve their long term prognosis.
Dr. John Thornback, Myconostica’s Chief Operating Officer, received the honour on behalf of the company at the award ceremony. Speaking at the event, Dr. Thornback said “Myconostica is delighted to have received this title in recognition of the innovative technology utilised in our original test for identifying Candida species, MycArray Yeast ID.
Dr. Thornback continues: “Having been the recipients of Bionow’s Biomedical Start Up of the Year Award in 2006 we are delighted to have been further recognised for our continued contribution to providing innovative diagnostic solutions for the treatment of invasive fungal diseases.”
Prof. Paul Brenchley said: “Receiving one award is fantastic, so to have our technology recognised by both the Northwest NHS Innovations Award and the Northwest Biomedical Awards in one week is a huge honour.”
Manchester based MTI Partners Investment Manager Mark Rahn said: “I am delighted that the University of Manchester and NHS projects have featured so well in recent awards events. MTI’s UMIP Premier Fund is a supporter of both Myconostica and Renephra and we are pleased that these awards recognise their recent strides forward.”